



<b>NAME OF APPLICANT</b>	Francois Meyer
<b>MEMBER IN GOOD STANDING</b>	Yes
<b>RECOMMENDED BY SOCIETY MEMBERS IN GOOD STANDING</b>	Mouna Jameleddine Yingyao Chen Wija Oortwijn
<b>POSITION APPLYING FOR</b>	Director
<b>ORGANIZATION NAME</b>	FM Consulting
<b>ORGANIZATION TYPE</b>	Consultancy
<b>POSITION WITH COMPANY</b>	Head
<b>COUNTRY OF RESIDENCE</b>	France
<b>CONFLICT OF INTEREST</b>	
<b>ARE YOU CURRENTLY SERVING ON ANY BOARDS?</b>	No
<b>IF YES, WHICH BOARD?</b>	-
<b>CAN THIS SERVICE ON ANOTHER BOARD GIVE RISE TO A CONFLICT OF INTEREST WITH HTAi BOARD SERVICE?</b>	No
<b>IF YES, PLEASE DECLARE YOUR CONFLICT OF INTEREST.</b>	-
<b>DO YOU HAVE ANY CONTRACTUAL AGREEMENTS WITH HTAi FOR SERVICES?</b>	No
<b>IF YES, PLEASE SPECIFY.</b>	-
<b>DO YOU HAVE ANY AFFILIATIONS, MEMBERSHIPS, CONTRACTS OR SPECIAL INTERESTS CONFLICTING WITH THE ROLE AND DUTIES AS AN HTAi DIRECTOR?</b>	No
<b>IF YES, PLEASE DECLARE YOUR CONFLICT OF INTEREST.</b>	-
<b>APPLICANT EXPERIENCE</b>	
<b>LEADERSHIP EXPERIENCE</b>	HTA
<b>PREVIOUS BOARD SERVICE. YES/NO</b>	Yes
<b>IF YES:</b>	
<b>HOW MANY YEARS?</b>	<ol style="list-style-type: none"> <li>1. HTAi - 6 years (2 terms)</li> <li>2. INAHTA – 2 years</li> <li>3. HTA Divison at HAS – 17 years</li> <li>4. French Medicines Agency - 8 years</li> </ol>
<b>WHICH BOARD POSITION?</b>	<ol style="list-style-type: none"> <li>1. Member</li> <li>2. Member</li> <li>3. Member</li> <li>4. Member</li> </ol>

<b>EXPERIENCE IN LEADERSHIP AND GOVERNANCE OF NOT-FOR-PROFIT AND FOR-PROFIT ORGANIZATIONS. YES/NO</b>	Yes.
<b>IF YES:</b>	
<b>HOW MANY YEARS?</b>	5 years
<b>TYPE OF EXPERIENCE</b>	Secretary General of a French association (VIF-fragiles) publishing a web media on health vulnerabilities (vulnerable populations, vulnerabilities in the healthcare system).
<b>LEVEL OF MANAGEMENT EXPERIENCE</b>	Middle Level of Management
<b>EXPERIENCE CHAIRING BOARD OR COMMITTEE YES/NO</b>	No
<b>IF YES:</b>	
<b>TYPE OF EXPERIENCE</b>	-
<b>NUMBER OF YEARS</b>	-
<b>PUBLIC SPEAKING EXPERIENCE YES/NO</b>	Yes
<b>IF YES:</b>	
<b>TYPE OF EXPERIENCE</b>	Presentation in congresses, chair of panels, chair of seminars
<b>NUMBER OF YEARS</b>	20+ years
<b>DO YOU UNDERSTAND THE DIFFERENCE BETWEEN GOVERNANCE AND MANAGEMENT</b>	Yes. Head of Department and member of the Board of Directors at French Medicines Agency and then Haute Autorité de Santé. 20+ years.
<b>STRATEGIC PLANNING EXPERIENCE? YES/NO</b>	No
<b>IF YES:</b>	
<b>TYPE OF EXPERIENCE</b>	-
<b>NUMBER OF YEARS</b>	-
<b>EXPERIENCE IN DEVELOPING GROWTH STRATEGIES AND PLANS? YES/NO</b>	Yes
<b>IF YES:</b>	
<b>TYPE OF EXPERIENCE</b>	Head of Department and member of the Board of Directors at French Medicines Agency and then Haute Autorité de Santé.
<b>NUMBER OF YEARS</b>	20+ years
<b>MEMBERSHIP RECRUITMENT AND ENGAGEMENT EXPERIENCE? YES/NO</b>	Yes
<b>IF YES:</b>	
<b>TYPE OF EXPERIENCE</b>	Experience in recruiting HTA bodies for cooperative projects
<b>NUMBER OF YEARS</b>	3 years
<b>PARTNERSHIP DEVELOPMENT EXPERIENCE? YES/NO</b>	Yes
<b>IF YES:</b>	

<b>TYPE OF EXPERIENCE</b>	European Network for Health Technology Assessment (EUnetHTA) Leader of a Work Package and Member of the Steering Group. Coordinator of a network of 14 HTA bodies for an EU-sponsored project (SEED) on Early Dialogues between HTA bodies and developers of Medicines or Medical Devices.
<b>NUMBER OF YEARS</b>	12 years
<b>PROGRAMS' EVALUATION EXPERIENCE? YES/NO</b>	Yes
<b>IF YES:</b>	
<b>TYPE OF EXPERIENCE</b>	Evaluation of research projects at French Medicines Agency and HAS
<b>NUMBER OF YEARS</b>	10 years
<b>FINANCIAL OVERSIGHT</b>	
<b>FINANCIAL LITERACY? YES/NO</b>	Yes
<b>IF YES:</b>	
<b>TYPE OF EXPERIENCE</b>	Basic
<b>NUMBER OF YEARS</b>	14 years
<b>EXPERIENCE WITH FINANCIAL STATEMENTS AND VARIANCE ANALYSIS? YES/NO</b>	No
<b>IF YES:</b>	
<b>TYPE OF EXPERIENCE</b>	-
<b>NUMBER OF YEARS</b>	-
<b>EXPERIENCE WITH FINANCIAL RISK IDENTIFICATION AND ASSESSMENT? YES/NO</b>	No
<b>IF YES:</b>	
<b>TYPE OF EXPERIENCE</b>	-
<b>NUMBER OF YEARS</b>	-
<b>COMMITTEE WORK</b>	
<b>WHICH BOARD ADVISORY COMMITTEES ARE YOU INTEREST TO SERVE ON?</b>	Annual Meeting Committee, Policy Forum Advisory Committee, Interest Group Advisory Committee.
<b>EXPLAIN WHY YOU SELECTED THE ABOVE COMMITTEES</b>	I am open to participate in any of the committees so this list is indicative.
<b>WHICH BOARD ADVISORY COMMITTEE(S), IF AVAILABLE, WOULD YOU BE INTERESTED TO CHAIR IN THE NEAR FUTURE?</b>	Policy Forum Advisory Committee, Interest Group Advisory Committee.
<b>EXPLAIN WHY YOU SELECTED THE ABOVE COMMITTEE(S)</b>	Again an indicative list.
<b>WOULD YOU BE INTERESTED IN BECOMING THE HTAi BOARD LIAISON FOR THE IJTAHC IN THE NEAR FUTURE? YES/NO</b>	No

**IF YES, PLEASE EXPLAIN YOUR EXPERTISE WITH ACADEMIC PUBLISHING/WRITING AND/OR SERVING ON EDITORIAL BOARDS OF INTERNATIONAL, PEER-REVIEWED JOURNALS.**

-

I am Dr. François Meyer, a seasoned medical professional with extensive experience in Health Technology Assessment (HTA), public health, and international health affairs. Since 2024, I have been working as an independent consultant focusing on HTA and various public health-related issues, leveraging my years of expertise to support diverse stakeholders in the health sector.

My journey in the healthcare field began with my medical degree from Montpellier School of Medicine, where I specialized in endocrinology and metabolic disorders. This foundation laid the groundwork for a multifaceted career that has spanned both clinical practice and health policy, in both the public and private sectors. At the outset of my career, I combined my work as a practicing physician seeing patients with responsibilities in teaching and clinical research in the hospitals of Montpellier. My clinical experience enriched my understanding of patient needs and the healthcare system, which has been invaluable in my subsequent roles.

From 1992 to 1997, I worked at Ciba-Geigy Laboratories and later Novartis, where I served as a Medical Advisor and Group Leader in Research and Development. I was involved in innovative research concerning respiratory diseases, rheumatology, and oncology, drafting expert reports and clinical trial protocols. This experience honed my skills in balancing scientific rigor with practical applications, ensuring that research directly informs patient care.

In 1997, I joined the French Medicines Agency (Afssaps, now ANSM) as Deputy Director for the evaluation of the safety, quality, and efficacy of pharmaceuticals. I was particularly involved in crisis management and press relations as well as the interface with political bodies (Ministry of Health, European Commission) during the development of new regulatory frameworks.

In 2003, I was appointed Secretary General of the Transparency Committee, tasked with implementing reforms in HTA for pharmaceuticals – an experience that would shape my understanding of health policy and governance.

My tenure at the National French Health Authority (HAS) from 2005 to 2021 was particularly transformative. I established and directed the Health Technology Assessment Division, where I integrated HTA across multiple technologies, including pharmaceuticals, medical devices, and public health interventions. My experience there allowed me to collaborate with national institutions and the European Commission, engaging in international cooperation on HTA through the EUnetHTA network. I am proud to have been a member of the Board of Directors of HTAi for two terms starting in 2012. I have also represented HAS on the INAHTA Board and participated in or organized numerous international meetings across Europe, North America, South America, Asia, and Australia.

Since 2022, as part of my consultancy, I have contributed, as a special advisor, to the work of RWE4Decisions, a multi-stakeholder network involving HTA bodies, payers, health professionals, patient associations, pharmaceutical companies to generate fit-for-purpose real-world evidence to inform HTA and payer decisions. I also co-founded a web media platform dedicated to exploring the social aspects of health, particularly as they pertain to fragile populations. This initiative allows me to continue advocating for patient-centered care and the importance of addressing health disparities.

My mother tongue is French, I am fluent in English and proficient in Spanish, a language that I learned recently to improve communication with the worldwide Spanish-speaking community. I am committed to bridging gaps in communication and understanding in the multilingual landscape of global health. My passion lies in fostering collaboration among stakeholders to improve health outcomes and ensure that advancements in health technology are equitably accessible to all.

I look forward to continuing my work in improving healthcare systems and policies and to engaging in further collaborative work through HTAi, aiming at making impactful contributions to the field of evidence-based healthcare and public health.

## **To all members of HTAi**

Dear Colleagues,

My name is François Meyer and I am presenting my candidacy for the position of Director on the HTAi Board.

We are living in a time when the evaluation of healthcare technologies has never been more critical. Regardless of a country's size or economic standing, difficult choices must be made. Both the collective interest and the needs of individual patients require that decisions about healthcare systems rest on rigorous, pragmatic, and science-based assessment — precisely what high-quality HTA is designed to deliver.

At the same time, HTA faces significant challenges: increasing budgetary pressures and, more concerning, growing attacks on scientific evidence itself. In this context, defending methodological rigor, transparency, and independence in HTA is essential.

Such a defense can only be effective through strong international collaboration. HTAi is the most relevant and credible platform for this collective effort. It is this conviction that strongly motivates me to run for a position on its Board of Directors for which I believe to have the necessary experience and availability.

I am pleased to provide an overview of my experience and qualifications in relation to this position.

### **Governance**

My career spans clinical medicine, pharmaceutical research, regulatory leadership, national HTA governance, and international collaboration. As Secretary General of the Transparency Committee and later founder and Director of the HTA Division at HAS, I worked at governance level, defining strategic direction, establishing methodological frameworks, and ensuring institutional accountability. Having served two terms on the HTAi Board, I am familiar with the Society's mission and governance culture and have consistently contributed with a strategic, long-term perspective.

### **Knowledge and Judgment**

For over two decades, I have led HTA activities across pharmaceuticals, medical devices, and public health interventions, addressing clinical effectiveness, safety, cost-effectiveness, organizational, and ethical dimensions. This experience enables me to critically assess assumptions, risks, and trade-offs underlying policy and business decisions. As a senior executive in a national authority, I also oversaw substantial budgets and financial performance aligned with strategic priorities.

### **Participation and Availability**

I have chaired committees, supervised expert groups, and participated in national and international governance bodies, including the HTAi and INAHTA Boards. In my current

role as an independent consultant, I have the flexibility to fully commit to Board and Committee responsibilities.

**Communication and Teamwork**

My work has involved sustained interaction with policymakers, clinicians, industry, patient groups, and international partners. I am accustomed to transparent, candid, and respectful deliberation, while upholding confidentiality and collective responsibility. Fluent in French and English and proficient in Spanish, I am comfortable engaging within HTAi's global membership. I value ethical conduct, stakeholder sensitivity, and solidarity in Board decisions.

**Overall Contribution**

Throughout my career, I have sought to strengthen institutions, promote methodological rigor, and foster international cooperation in HTA. I remain committed to contributing to HTAi's long-term sustainability, strategic oversight, and continued advancement of evidence-based healthcare.

Sincerely,  
Dr. François Meyer